Advanced Critical Care With Stem Cell Therapy

Investor Overview

Forward Looking Statements

This presentation has been prepared solely for informational purposes. This presentation includes, and our responses to various questions may include, "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by those sections. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy and our future financial performance, including our operations, economic performance, financial condition, prospects and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "potential," "should," "suggest," "will" or other similar expressions. The forward-looking statements are not historical facts, and are based upon the Company's current expectations, beliefs, estimates, and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond the Company's control. The Company's expectations, beliefs and projections are expressed in good faith and the Company believes there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, estimates, and projections will result or be achieved, and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances or other changes affecting forward-looking information except to the extent required by applicable securities laws.

Information contained in this presentation has been compiled from sources believed to be credible and reliable. However, we cannot guarantee such credibility and reliability. The forecasts and projections of events contained herein are based upon subjective valuations, analyses and personal opinions.

Sanostem Corporate Summary

- Sanostem is a clinical-stage biotech company focused on the next generation of therapies for critical health issues
  - A leader in the field of allogeneic cell therapy, which expands cells from healthy donors into a cellular therapy that acts to minimize inflammatory damage following an injury and helps modulate healing of the damaged tissue.
  - 20 years of research on this technology; 15 years of clinical trials; 1200 patients dosed with an excellent safety record
  - Leader in larger-scale manufacturing

- We are focused on major markets with high unmet patient need
  - platform technology with significant preclinical data packages in areas including Graft vs Host Disease, Multiple Sclerosis, Traumatic Brain Injury
  - We are currently in advanced development stroke Phase 2 B clinical trial.

- We are set up to succeed
  - New and experienced management team
  - Lean operating model focused on achieving clinical milestones
  - Additional focus on spinning off non-core technologies, and cryo-storage technology
  - Pursuing additional global and regional partnerships to establish commercial expertise and networks

SANOSTEM
Restoring lives with SanoMSC

Proprietary Cell Therapy Platform

Off-The-Shelf Product
Allogenic, no tissue matching, IV administration

Scalability, Stability & Consistent Product Quality
Single adult donor capable of generating hundreds of thousands of doses in proprietary process

Starting Phase 2 B cell therapy
Cell therapy study in ischemic stroke, with RMAT, SPA and Fast-Track
Regulatory Designations from FDA

Well-Characterized Mechanism of Action
Applicable Across Many High Value Indications

Platform Advantages:
Innovation From Donor to Patient

- A leader in larger-scale manufacturing development
- Several years of successful GMP
- One healthy human donor can be expanded to hundreds of thousands of clinical & commercial doses
  - 1.2 Billion cells / dose
- Product can be prepared and administered from pharmacy to patient in less than one hour

One Donor ➡ Master and Working Cell Banks ➡ Large Scale Cell Expansion in Bioreactors ➡ Hundreds of thousands of doses to treat patients

SANOSTEM
Restoring lives with SanoMSC

Lead Indications

	Ischemic Stroke
Frequency	~800,000 strokes per year in the US
Patient Impact	Leading cause of disability and **third highest cause of death**
Economic Burden	Over **$55 billion** cost to the health care system annually
Treatment Options	Current standard of care includes thrombolytics and mechanical thrombectomy, which reach **only 30%** of patients
Addressable Population	**43%** of all strokes are **moderate to severe ischemic strokes**, the focus of our trial with MultiStem

Cell Therapy Platform: Opportunities Across Serious Unmet Need Indications

PHASE 3 — Ischemic Stroke	IND READY — Hemorrhagic Stroke	NONCLINICAL — Parkinson's Disease	NONCLINICAL — Rheumatoid Arthritis
PHASE 2 — Trauma	IND READY — Hypoxic Ischemia (E)	NONCLINICAL — Alzheimer's Disease	NONCLINICAL — Congestive Heart Failure
PHASE 2/3 — Acute Respiratory Distress Disorder	IND READY — Traumatic Brain Injury	NONCLINICAL (G) — Lysosomal Storage Disorders	NONCLINICAL — Peripheral Vascular Disease
PHASE 2/3 (G) — Graft vs Host Disease	IND READY (E) — Spinal Cord Injury	NONCLINICAL — Multiple Sclerosis	DEVELOPMENT — Animal Health: Canine
PHASE 2 — Acute Myocardial Infarction	NONCLINICAL — Acute Radiation Syndrome	NONCLINICAL — Alcoholic Hepatitis	DEVELOPMENT — Animal Health: Equine
IND READY — Transplantation	NONCLINICAL — Epilepsy	NONCLINICAL — Wound Healing	DEVELOPMENT — Animal Health: Feline

G Orphan Granted E Orphan Eligible

Ischemic Stroke

Overview
Unmet Medical Need
Clinical Trials

Stroke Overview

Background



Ischemic Stroke

Caused by a blocked artery



Hemorrhagic Stroke

Caused by leaking or bursting of a blood vessel

- A stroke occurs when the blood supply is interrupted or reduced to part of the brain. This prevents brain cells from getting oxygen and nutrients, leading to cell death and tissue loss
- Stroke is the leading cause of disability and the third leading cause of death in the US
- Each year nearly 800,000 people in the US suffer a stroke
- About 43% of all strokes are moderate to severe ischemic strokes, the focus of our trial

Impact

High Unmet Need

Only 30% of patients qualify for current standard of care (thrombolytics / mechanical thrombectomy) both of which have limited treatment windows and patient eligibility

High Burden on Healthcare System

Stroke patients have a $55 billion impact on the healthcare system

SanoStem Solution

-Expands treatment window to 36 hours
-Potential to provide additive benefit to standard of care
-Treats bodily response to clot formation and prevents secondary injury and complications caused by the stroke

SANOSTEM
Restoring lives with SanoMSC

Unmet Medical Need in Stroke: Only 2 Approved Ischemic Stroke Treatments

	Thrombolytics	Mechanical Thrombectomy	Stem Cell Therapy
Mechanism of Action	Clot dissolving medications	Removal of the clot using a catheter device	Modulation of the immune system
Applicability	Only 15% of ischemic stroke patients are eligible for tPA within 4.5 hours	Only ~10% of ischemic stroke patients are eligible due to the location of the clot	Potentially applicable to 90 - 95% of all ischemic stroke patients because of extended therapeutic window and mechanism of action
Benefit	Improved recovery in ~15% of patients who receive tPA at 90 days with little additional improvement at Day 365	Improved recovery comparable to tPA at 90 Days with no clinically meaningful improvement from 90-365 Days	Promotes recovery, projected clinically meaningful benefit. Can be given independently or following thrombolytics and/or thrombectomy at both 90 Days and 365 Days
Safety / Complications	Associated with hemorrhagic transformations in 2 - 4% of patients	Potential vascular damage and cerebral edema	2 completed studies and 3rd ongoing with a favorable tolerability profile

Therapeutic Window



Scalable Manufacturing Process

15 Years of Production Experience and Advancements in Cell Therapy:

- Proven expertise in efficient, high yielding and innovative processes
- Establishment of an essentially closed manufacturing process - unique characteristic in the Cell & Gene Therapy industry
- Advancement of a large-scale cell therapy manufacturing process at increasing scales to support commercial manufacturing – building upon expertise from Cell Factories to Bioreactors

T-Flask	2D	3D 1.0	3D 2.0
• Used in Process Development Activities • Pre 2007	• 10 Layer Cell Factory • Year 2007 to present • ~ 6 Doses per Batch • 150 Production Runs Completed **Most Cell Therapy Companies are Here**	• 4 x 40 Liter Single Use Bioreactors • Year 2017 to 2020 • 20 – 25 Doses per Batch • 20+ Production Runs Completed	• 1 x 200L FPI/1 x 500L DP Single Use BRs • 2020 to present • 75-100 Doses per 500 L Bioreactor • 2 Development Runs Completed • Xeno-free process

Thank you!